The Week That Sold the Degrader Thesis
Kymera's dual Fast Track, Gilead's $45M option exercise, and Neomorph's $100M raise validate targeted protein degradation across immunology and oncology in a single week.
Jeff Martin
Pancreatic Cancer Finally Has a Weak Spot. Here’s Who’s Going After It.
Revolution Medicines' Phase 3 daraxonrasib data validates a growing wave of early-stage companies attacking RAS.
Allogene Posted the Data Off-the-Shelf CAR-T Has Been Waiting For
Allogene's pivotal ALPHA3 data validates off-the-shelf CAR-T and gives a new generation of allogeneic companies something to build on.
The Push To Unlock Brain Cancer Is Heating Up. Time To Pay Attention.
In five weeks, 16 companies made moves against brain cancer. Gene therapies, oral pills, oncolytics, sonodynamic therapy. Something shifted.
Next-Gen Research Tools: Breaking the Preclinical Data Paradox
This report profiles 79 companies across 8 categories building better preclinical research tools, from organs-on-chips to digital twins, that are breaking the paradox between founders who need data and investors who need conviction.
The Oncolytic Virus Graveyard Gets Another Headstone
Replimune receives FDA Complete Response Letter for RP1 in advanced melanoma, scales back operations.
What If Your Antiviral Had an Immune System?
ArkBio doses first cohort in Phase I trial of AK0406, a first-in-class antiviral drug-Fc conjugate targeting influenza.
Vivatides Raises $54M to Escape the Liver
Vivatides Therapeutics closes an oversubscribed $54M Series A for its extrahepatic RNA delivery platform.
Deck Bio
Multi-target T cell engagers redirecting immunity against intracellular cancer antigens in solid tumors.
Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.
Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.